These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1173 related items for PubMed ID: 18461550

  • 1. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [Abstract] [Full Text] [Related]

  • 2. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
    Wright D, Spencer K, Kagan K K, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
    [Abstract] [Full Text] [Related]

  • 3. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [Abstract] [Full Text] [Related]

  • 4. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [Abstract] [Full Text] [Related]

  • 5. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [Abstract] [Full Text] [Related]

  • 6. Screening for trisomy 21 by maternal age fetal nuchal translucency thickness and maternal serum sample.
    Torella M, Tormettino B, Zurzolo V, Labriola D, Ambrosio D, Stradella L, Schettino MT, De Franciscis P.
    Minerva Ginecol; 2013 Dec; 65(6):653-9. PubMed ID: 23881389
    [Abstract] [Full Text] [Related]

  • 7. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [Abstract] [Full Text] [Related]

  • 8. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [Abstract] [Full Text] [Related]

  • 9. Prospective validation of first-trimester combined screening for trisomy 21.
    Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
    [Abstract] [Full Text] [Related]

  • 10. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [Abstract] [Full Text] [Related]

  • 11. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Hoopmann M, Abele H, Alkier R, Lüthgens K.
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [Abstract] [Full Text] [Related]

  • 12. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A, Pruggmayer M, Kamin G, Fritzer E, Harris C, Arnold N, German Speaking Down Syndrome Screening Group.
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [Abstract] [Full Text] [Related]

  • 13. Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
    Kagan KO, Staboulidou I, Cruz J, Wright D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2010 Nov; 36(5):542-7. PubMed ID: 20503223
    [Abstract] [Full Text] [Related]

  • 14. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
    Wright D, Abele H, Baker A, Kagan KO.
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
    [Abstract] [Full Text] [Related]

  • 15. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A.
    Fetal Diagn Ther; 2006 Sep; 21(3):264-8. PubMed ID: 16601335
    [Abstract] [Full Text] [Related]

  • 16. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M, Persico N, Kagan KO, Gazzoni A, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [Abstract] [Full Text] [Related]

  • 17. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [Abstract] [Full Text] [Related]

  • 18. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D, Langlois S, Douglas Wilson R, SOGC GENETICS COMMITTEE, CCMG PRENATAL DIAGNOSIS COMMITTEE.
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [Abstract] [Full Text] [Related]

  • 19. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [Abstract] [Full Text] [Related]

  • 20. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N, Egić A, Filimonović D, Marinković M, Damnjanović-Pazin B, Milovanović Z, Joksić I, Branković S, Lukić R, Mandić V, Cerović N, Mojović D, Plamenac S, Stanković M, Maglić D, Mikovć Z.
    Srp Arh Celok Lek; 2012 May; 140(9-10):606-11. PubMed ID: 23289277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.